A new University of Kent start-up, Sirius Proteins, has launched a biotechnology solution to significantly reduce the cost and complexity of producing proteins used in cancer therapies, vaccines, and diagnostic tests. The technology, known as Vesicle Nucleating Peptide (VNp), enables bacterial cells to package proteins into membrane-bound vesicles, simplifying their collection and purification. This innovation addresses challenges with unstable or toxic proteins that are traditionally difficult to manufacture. Researchers led by Professor Dan Mulvhill demonstrated that VNp increases protein yields while making production more accessible for researchers and pharmaceutical companies. Additional studies at the LFS Central Laser Facility revealed potential applications beyond medicine, including targeted drug delivery and therapeutic development. The breakthrough could democratize protein production, accelerating drug development and reducing healthcare costs. This advancement highlights the intersection of biotechnology and industrial innovation in advancing medical treatments.

'Symptom triggered testing', prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat, can pick up early stage aggressive ovarian cancer in 1 in 4 of...

VI-RADS Scores for Muscle-Invasive Bladder Cancer / bladder cancer, bladder cancer care, bladder cancer research, cancer, Cancer diagnostics, cancer outcomes,

Abbott is investigating a cybersecurity incident involving unauthorized access to a limited number of internal systems within its Cancer Diagnostics division. The company says the incident did not affect business operations, product availability, manufacturing, laboratories, or any other Abbott activities or sites. #Abbott

The cyberattack follows Abbott’s recent $21 billion purchase of Exact Sciences. Abbott did not disclose what kind of information was accessed.

Wednesday, October 22, 2025 at 12:00 PM Eastern Daylight Time.

Strategic collaboration aims to improve early diagnosis

Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK

Collaboration expands AI-based risk profiling tools

Almost 700,000 women to be recruited to study as government fires starting gun on cancer strategy.

US Minimal Residual Disease Testing Market share register 507.48 USD Million in 2024, projected to grow 11.36 % CAGR to reach USD Million 1657.77 during the forecast period 2025 - 2035.